Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients

Trial Profile

Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2016

At a glance

  • Drugs Q 301 (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Qurient Co
  • Most Recent Events

    • 18 May 2016 Status changed from active, no longer recruiting to completed.
    • 08 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.
    • 20 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top